https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-17 / Int J Hyperthermia 2013;29(1):8-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-17 / Int J Hyperthermia 2013;29(1):8-162012-12-17 00:00:002012-12-17 00:00:00Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-832012-12-11 00:00:002012-12-11 00:00:00Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-105
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-1052012-11-21 00:00:002019-02-15 09:17:14Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-972012-11-01 00:00:002019-02-15 09:17:15Heat shock proteins (HSPs) based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-92012-11-01 00:00:002012-11-01 00:00:00[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-24 / Int J Hyperthermia 2012;28(8):707-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-24 / Int J Hyperthermia 2012;28(8):707-142012-09-24 00:00:002019-02-15 08:39:16Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-912012-08-01 00:00:002012-08-01 00:00:00Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-612012-07-31 00:00:002019-02-15 08:39:15Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-27 / Int J Hyperthermia 2012;28(7):597-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-27 / Int J Hyperthermia 2012;28(7):597-6042012-07-27 00:00:002012-07-27 00:00:00Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-222012-07-03 00:00:002019-02-15 09:18:19Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
